^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FGFR2b expression

i
Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
Entrez ID:
1d
Advanced Intrahepatic Cholangiocarcinoma (iCCA): Investigating Co-Molecular Alterations (AIOM 2024)
The FGFR and IDH-1 pathways are the primary targets for therapy, with FGFR-2 and IDH-1 inhibitors, such as Pemigatinib and Ivosidenib respectively, already available on the market. This prospective study validates the prevalence of mutations documented in the literature and underscores the significance of NGS in presenting supplementary therapeutic avenues. Moreover, we demonstrated the role of other potential targets co-expressed with FGFR2 or IDH1 which could represent a crucial opportunity for novel combinations or sequences therapies.
BRCA Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NTRK (Neurotrophic receptor tyrosine kinase) • CA 19-9 (Cancer antigen 19-9)
|
TP53 mutation • KRAS mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • CDKN2A mutation • BAP1 mutation • FGFR2 expression • FGFR2b expression
|
FoundationOne® CDx
|
Pemazyre (pemigatinib) • Tibsovo (ivosidenib)
1m
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors. (PubMed, Cancer Sci)
To advance our understanding of the role of breast cancer driver genes' mutational status with pathological complete response (pCR; ypT0/isypN0) prediction and to identify distinct gene sets for MTIs like eribulin and paclitaxel, we carried out targeted genomic (n = 50) and whole transcriptomic profiling (n = 64) of TNBC tumor samples from the Japan Breast Cancer Research Group 22 (JBCRG-22) clinical trial. Differential enrichment analysis of the HRD-high group posttreatment tumors revealed significant correlation (p = 0.006) of the glycan degradation pathway. FGFR2 expression and the differentially enriched pathways play a role in the response and resistance to MTIs containing carboplatin treatment in TNBC patients.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • HRAS (Harvey rat sarcoma viral oncogene homolog) • BRCA (Breast cancer early onset)
|
TP53 mutation • BRCA2 mutation • PIK3CA mutation • HRD • PTEN mutation • FGFR2 mutation • HRAS mutation • BRCA mutation • FGFR2 expression • FGFR2b expression • High HRD score
|
carboplatin • paclitaxel • Halaven (eribulin mesylate)
2ms
Developing New Peptides and Peptide-Drug Conjugates for Targeting the FGFR2 Receptor-Expressing Tumor Cells and 3D Spheroids. (PubMed, Biomimetics (Basel))
Results demonstrated that Trimer-pep conjugated with DOX showed the highest permeation, while the ACSAG conjugate also demonstrated reasonable permeation of the drug. These results indicate that these peptides may be further explored and potentially utilized to create drug conjugates for targeting tumor cells expressing FGFR2 for developing therapeutics.
Journal • Tumor cell
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion • FGFR2 expression • FGFR2b expression
6ms
FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs. (PubMed, Cell Mol Biol Lett)
This study revealed the unknown role of FGFR2 signalling in activation of autophagy and regulation of the p62/Keap1/Nrf-2 interdependence, which has a negative impact on the response of ER+ BCa cells to anti-ER therapies. The data from in silico analyses suggest that expression of Nrf-2 could act as a marker indicating potential benefits of implementation of anti-FGFR therapy in patients with ER+ BCa, in particular, when used in combination with anti-ER drugs.
Journal
|
ER (Estrogen receptor) • FGFR2 (Fibroblast growth factor receptor 2) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • SQSTM1 (Sequestosome 1)
|
ER positive • FGFR mutation • FGFR2 expression • FGFR2b expression • NFE2L2 expression
8ms
Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. (PubMed, Virchows Arch)
FGFR2::BICC fusion was detected in a case of cHCC-CCAs. FGFR2 genetic alterations may be prevalent in cHCC-CCAs as well as small duct-type iCCAs, which suggest cHCC-CCAs may also be a possible therapeutic target of FGFR2 inhibitors.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • BICC1 (BicC Family RNA Binding Protein 1) • NES (Nestin)
|
FGFR2 fusion • FGFR2 expression • FGFR2b expression • NES expression
8ms
Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD (clinicaltrials.gov)
P=N/A, N=120, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
Trial completion date • Trial primary completion date
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 expression • FGFR2b expression
8ms
FGFR2 and miR-889-3p expression in oral cancer is associated with cervical lymph node metastasis. (PubMed, Oral Dis)
Decreased expression of miR-889-3p in OSCC tumours suggests that miR-889-3p functions as a tumour suppressor gene. Overexpression of FGFR2 further proves the role of miR-889-3p in the regulation of the FGFR2 pathway. This was further confirmed by showing differences in miR-889-3p expression in positive and negative LNM cases.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2 expression • FGFR2b expression
9ms
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies. (PubMed, Sci Rep)
This last finding entails that also this setting of patients could benefit from FGFR targeted therapies, widening indication of these drugs for iCCA patients beyond current approval. Future clinical studies are therefore encouraged to confirm this hypothesis.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGF10 (Fibroblast Growth Factor 10)
|
FGFR2 mutation • FGFR2 expression • FGFR2b expression • FGFR2 C382R • FGFR2 F276C • FGFR2 Y375C • FGFR wild-type • FGFR2 wild-type
1year
EXPRESSION AND CLINICOPATHOLOGICAL SIGNIFICANCE OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) IN COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA (AASLD 2023)
FGFR2 expression was detected in cHCC-CCAs as frequently as small duct-type iCCAs. This finding suggests a possible therapeutic indication of FGFR2 inhibitors for the patients with cHCC-CCAs.
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
|
FGFR2 fusion • FGFR2 expression • FGFR2b expression
1year
Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype. (PubMed, J Clin Transl Hepatol)
FISH achieved satisfactory concordance with NGS, has potential value for FGFR2 screening for targeted therapies. FGFR2 detection should be prioritized for unique clinical subgroups in ICC, which features a histological small duct subtype, early clinical stage, and reduced mucus production.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BICC1 (BicC Family RNA Binding Protein 1)
|
PD-L1 expression • KRAS mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • FGFR2 rearrangement • FGFR2 expression • FGFR2b expression
1year
Spatial distribution and functional relevance of FGFR1 and FGFR2 expression for glioblastoma tumor invasion. (PubMed, Cancer Lett)
Comparative analysis of RNA-sequencing data of FGFR1 and FGFR2 knockdown glioblastoma cells revealed a FGFR1-specific gene regulatory network associated with tumor invasion. Our study reveals new gene candidates linked to FGFR1-mediated glioblastoma invasion.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression • FGFR2 expression • FGFR2b expression
over1year
Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway. (PubMed, Sci Rep)
Moreover, TAX evidently inhibited the tumor growth in nude mice and the expression of c-Myc, cyclin D1, p-AKT and FGFR2 were down-regulated in xenograft tumor. These results indicate that TAX suppresses the proliferation of androgen-independent PCa cells via inhibiting the activation of PI3K/AKT signaling pathway and the expression of FGFR2, which means TAX may be a novel anti-tumor agent for later PCa treatment.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1)
|
MYC expression • CCND1 expression • FGFR2 expression • FGFR2b expression
over1year
Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse. (PubMed, J Transl Med)
In depth spatial in situ sequencing showed potential to provide a deeper understanding of the underlying mechanisms involved in the recurrence of disease and revealed novel potential predictive biomarkers for disease relapse in colon cancer stage II patients. Our open-access GTC-tool allowed us to accurately capture the tumour compartment and quantify spatial gene expression in colon cancer tissue.
Journal • Gene Signature
|
FGFR2 (Fibroblast growth factor receptor 2) • MMP11 (Matrix Metallopeptidase 11)
|
FGFR2 expression • FGFR2b expression
over1year
The association of FGFR2 expression and splice isoforms with breast cancer subtypes. (EACR 2023)
The expression of FGFR2, and its isoforms, relate to breast cancer subtypes. FGFR2 expression is related to maintaining epithelial characteristics of breast cancer whereas low FGFR2 is associated with more aggressive, basal forms.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FGFR2 (Fibroblast growth factor receptor 2)
|
EGFR positive • FGFR2 expression • FGFR2b expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
over1year
Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization (PubMed, Arkh Patol)
Clone EPR24075-418 showed the best result in assessing the expression of FGFR2: the correlation with FISH results in reaction 3+ was 100%. Due to the high heterogeneity of FGFR2 expression, it is recommended to either examine the material of the primary tumor and metastasis, or evaluate a large volume of the primary tumor.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 amplification • FGFR2 expression • FGFR2b expression
|
crolibulin (EPC2407)
over1year
Identification of cancer-related genes FGFR2 and CEBPB in choledochal cyst via RNA sequencing of patient-derived liver organoids. (PubMed, PLoS One)
The study identified dysregulated genes related to cancer pathways in CC patients suggesting cancer risk. The findings suggest that the elevated expression of FGFR2 and CEBPB in liver may contribute to cancer development in CC patients.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 expression • FGFR2b expression
almost2years
The Simultaneous Anti-FGFR Inhibitor and Gemcitabine Therapy Against Intrahepatic Cholangiocarcinoma with FGFR-fusion is a Promising Combination Therapy (APASL 2023)
Background and Aim: FGFR2 fusion gene alteration has observed in 15-20% of intrahepatic cholangiocarcinoma (iCCA), and anti-FGFR inhibitor, Pemigatinib, is commercially available to patients who have FGFR2 alteration. Combination administration of anti-FGFR inhibitor and GEM showed synergistic effect to the FGF activated iCCA cell line. 1001
Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2)
|
FGFR2 fusion • FGFR fusion • FGFR2 expression • FGFR2b expression
|
gemcitabine • Pemazyre (pemigatinib)
almost2years
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models. (PubMed, Anticancer Drugs)
DZB inhibited growth of three tumor xenograft models with reported expression or amplification of CSF1R, whereas the specific FGFRi, pemigatinib, had no efficacy. Similar modulation of the tumor microenvironment was observed in an FGFR-insensitive syngeneic bladder model, MBT-2. These data confirm CSF1R as an important oncology target for DZB and provide mechanistic insight for the ongoing clinical trials, in which DZB is combined with the PD-L1 antibody, atezolizumab.
Preclinical • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Tumor cell
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 expression • FGFR2b expression
|
Tecentriq (atezolizumab) • Pemazyre (pemigatinib) • derazantinib (ARQ 087)
almost2years
Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma. (PubMed, J Clin Transl Hepatol)
Knockout of RBM34 significantly inhibited cell proliferation, migration, and xenograft tumor growth, and sensitized HCC cells to sorafenib treatment. RBM34 inhibition reduced FGFR2 expression and affected PI3K-AKT pathway activation in HCC cells. Our study suggests that RBM34 may serve as a new prognostic marker and therapeutic target of HCC.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 expression • FGFR2b expression
|
sorafenib
almost2years
Prognostic significance for recurrence of FGFR2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection. (PubMed, Hepatol Res)
We demonstrated that FGFR2 high expression was the independent prognostic factor for recurrence of resected ICC.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • CD8 (cluster of differentiation 8)
|
FGFR2 fusion • FGFR fusion • FGFR2 overexpression • FGFR2 expression • FGFR2b expression
almost2years
Agreement between FGFR2 immunohistochemistry assays and fluorescence in situ hybridization (FISH) in metastatic gastric cancer: A comparison study. (ASCO-GI 2023)
Pairwise comparison of 4 tests based on the same patient population was performed: 3 IHC assays [Abcam clone EPR24075-418, R&D clone 98706, Santa Cruz clone C-8] and one FISH test... Among patients who were negative by FISH, 86%-93% of the patients were negative by IHC assay (Abcam). Among patients who were positive by FISH, 75-80% of them were positive by IHC. FISH should not be recommended as a substitute for a FGFR2 IHC assay due to high probability of false negative prediction as a result of intratumoral heterogeneity and low PCC.
Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 amplification • FGFR2 expression • FGFR2b expression
|
crolibulin (EPC2407)
2years
Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma. (PubMed, Transl Cancer Res)
FGFR1 and FGFR2 may participate in the occurrence of SCC of the throat: (I) positive FGFR1 and FGFR2 expressions are not associated with gender, age, smoking history, alcohol consumption history, tumor diameter, lymph node metastasis, degree of differentiation, or TNM stage. (II) FGFR2 increases successively with higher FGFR1 expression and with a positive correlation in laryngeal SCC.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression • FGFR2 expression • FGFR2b expression
over2years
Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
Our work sheds light on the potential role of FGFR2 in the development of ccRCC, suggesting that FGFR2 may serve as a prognostic marker and potential therapeutic target for patients with ccRCC.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2 expression • FGFR2b expression
over2years
FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. (PubMed, Mol Oncol)
In vitro analyses showed that FGF7/FGFR2 signalling: (a) abolished the effect of P4 on E2-promoted 3D cell growth and response to tamoxifen; (b) regulated ER and PR expression and activity; (c) increased formation of ER-PR complexes; and (d) reversed P4-triggered deregulation of ER-dependent genes. Our results demonstrate for the first time that the FGF7/FGFR2-JunB axis abolishes the modulatory effects of PR on ER-associated biological functions in premenopausal ER+ BCa. This may provide foundations for a better selection of patients for FGFR-targeting therapeutic strategies.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • FGFR2 (Fibroblast growth factor receptor 2) • FGF7 (Fibroblast Growth Factor 7) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
|
ER positive • FGFR2 overexpression • FGFR2 expression • FGFR2b expression • PGR expression
|
tamoxifen
over2years
Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients. (PubMed, J Clin Med)
Our study suggested that FGFR2 expression can be used to classify HCC patients based on HCV infection. This FGFR2-based classification may lead to new therapeutic strategies against HCV-positive HCC subtypes.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR2 overexpression • FGFR1 expression • FGFR2 expression • FGFR2b expression • FGFR3 expression
over2years
Effect of miR-381-3p/FGF7 axis on the osteogenic differentiation of bone marrow mesenchymal stem cells through MEK/ERK signaling pathway. (PubMed, Tissue Cell)
The BMMSCs from patients with MBD (MBD‑MSC) or normal participants (Normal‑MSC) were isolated and induced to differentiation with dexamethasone. Furthermore, the application of LY3214996, the inhibitor of ERK also verified these outcomes. MiR-381-3p directly targeting FGF7 modulated the osteogenic differentiation via MEK/ERK signaling pathway in BMMSCs.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • CD44 (CD44 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • THY1 (Thy-1 membrane glycoprotein) • ENG (Endoglin) • MIR381 (MicroRNA 381) • FGF7 (Fibroblast Growth Factor 7)
|
FGFR2 expression • FGFR2b expression • CD44 positive
|
dexamethasone • temuterkib (LY3214996)
over2years
Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients. (PubMed, Cancer Diagn Progn)
HER2-positive GC patients, without overexpression of FGFR2, exhibited an improved prognosis and response rate to trastuzumab combination chemotherapy. Assessment of intra-tumoral FGFR2 expression could be helpful in predicting the prognosis and response to trastuzumab in HER2-positive GC patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 expression • EGFR positive • FGFR2 overexpression • FGFR2 expression • FGFR2b expression
|
Herceptin (trastuzumab)
over2years
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. (PubMed, Life Sci)
Inhibition of FGFRs by infigratinib enhanced the antitumor effect of Gem in CCA cells through downregulation of the FGFR/AKT/mTOR, FGFR/STAT3 and EMT signaling pathways.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • VIM (Vimentin) • CCNA2 (Cyclin A2) • SNAI2 (Snail Family Transcriptional Repressor 2) • CCNB1 (Cyclin B1)
|
FGFR2 expression • FGFR2b expression
|
gemcitabine • Truseltiq (infigratinib)
over2years
Fusion genes: Novel therapeutic targets for gastric signet ring cell carcinoma (AACR 2022)
Our observation revealed that fusion genes were recurrent in GSRCC and might associate to shorter OS. FGFR2 fusion genes were recurrent in GSRCC and FGFR2 inhibitors might be a new therapeutic target for GSRCC.
Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • FGFR2 (Fibroblast growth factor receptor 2) • TACC2 (Transforming Acidic Coiled-Coil Containing Protein 2)
|
TMB-L • FGFR2 fusion • FGFR2 expression • FGFR2b expression
over2years
Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study (AACR 2022)
In further studies, the evaluation of FGFR2 amplification seems to be important. >
Clinical • P1 data • PK/PD data
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 amplification • FGFR2 expression • FGFR2b expression
|
alofanib (RPT835)
over2years
FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort. (PubMed, PLoS One)
FGFR2 expression was associated with a lower tumor grade and intestinal phenotype (p≤0.0001). FGFR2-positive diffuse-type GCs classify a small subset of patients with a poor tumor specific survival (5.29±1.3 vs. 14.67±1.9 months; p = 0.004).
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 amplification • FGFR2 overexpression • FGFR2 expression • FGFR2b expression
over2years
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma With Comprehensive Genomic Profiling. (PubMed, J Mol Diagn)
P2; Cell lines expressing diverse FGFR2 fusions were sensitive to pemigatinib. F1CDx demonstrated sensitivity, reproducibility, and high concordance with clinical utility in identifying patients with FGFR2 rearrangements that may benefit from pemigatinib treatment.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion • FGFR2 rearrangement • FGFR2 expression • FGFR2b expression
|
FoundationOne® CDx
|
Pemazyre (pemigatinib)
almost3years
FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis. (PubMed, Cancer Sci)
Consistently, the MEK1/2 inhibitor, trametinib, potentiated CHK1 inhibitor-mediated cell death in these cells. These results suggested that FGFR2 loss might be prone to highly effective CHK1i treatment. In conclusion, extreme cellular dependency of ERK activation may imply a possible application for the MEK1/2 inhibitor, either as a single inhibitor or in combination with CHK1i in MYCN-amplified neuroblastomas.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification • FGFR2 expression • FGFR2b expression
|
Mekinist (trametinib)
almost3years
FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. (PubMed, Mol Oncol)
Cell-based screening of FGFR inhibitors with potential for clinical repurposing (NVP-BGJ398, nintedanib, dovitinib and ponatinib) revealed greater sensitivity of fusion-gene-positive versus -negative rhabdomyosarcoma cell lines and was shown to be correlated with high expression of FGFR2 and its specific ligand, FGF7. FGFR inhibition with NVP-BGJ398 reduced viability and was synergistic with SN-38, the active metabolite of irinotecan. In vivo, NVP-BGJ398 abrogated xenograft growth and warrants further investigation in combination with irinotecan as a therapeutic strategy for fusion-gene-positive rhabdomyosarcomas.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR4 (Fibroblast growth factor receptor 4) • PAX3 (Paired Box 3)
|
FGFR2 fusion • FGFR2 overexpression • FGFR2 expression • FGFR2b expression • PAX3-FOXO1 fusion
|
Iclusig (ponatinib) • Truseltiq (infigratinib) • irinotecan • nintedanib • dovitinib (TKI258)
3years
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. (PubMed, Dig Dis Sci)
FGFR2 protein expression by immunohistochemistry has high specificity and therefore could be used to imply the presence of FGFR2 genomic alterations in the context of a positive test. In the case of a negative test, NGS or FISH would be necessary to ascertain cases with FGFR2 genomic alterations.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion • FGFR2 expression • FGFR2b expression
3years
FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma. (PubMed, J Transl Med)
FGFR2 alterations were recurrent in PC GC and FGFR2 inhibitors might be a new therapeutic target for PC GC.
Journal • Tumor Mutational Burden
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • FGF19 (Fibroblast growth factor 19) • LRP1B (LDL Receptor Related Protein 1B) • CDH1 (Cadherin 1) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
|
TP53 mutation • ARID1A mutation • FGFR2 mutation • TMB-L • FGFR2 fusion • FGFR2 rearrangement • FGFR2 expression • FGFR2b expression
3years
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations (SABCS 2021)
Futibatinib had single agent activity of selected breast cancer PDX models. FGFR2 activating mutations and amplification may represent rare but promising therapeutic targets to FGFR inhibition.
Clinical • Preclinical
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • BICC1 (BicC Family RNA Binding Protein 1)
|
FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR2-BICC1 fusion • FGFR1 expression • FGFR2 expression • FGFR2b expression • FGFR4 expression • FGFR3 Y375C • FGFR2 Y375C
|
Lytgobi (futibatinib)
3years
Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, University Hospital, Strasbourg, France | Trial completion date: Aug 2026 --> Aug 2029 | Trial primary completion date: Jul 2026 --> Jul 2029
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression
over3years
Long Non-coding RNA ASNR Targeting miR-519e-5p Promotes Gastric Cancer Development by Regulating FGFR2. (PubMed, Front Cell Dev Biol)
Lnc_ASNR and FGFR2 were both targeted to miR-519e-5p, and they were negatively correlated with the expression of miR-519e-5p. All investigations indicated that Lnc_ASNR functioned as a ceRNA targeting miR-519e-5p and facilitated GC development by regulating the pathway of miR-519e-5p/FGFR2.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 expression • FGFR2b expression